Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it has received additional clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug HSK31858. The drug, a reversible dipeptidyl peptidase 1 (DPP1) inhibitor, is now approved for assessment in chronic obstructive pulmonary disease (COPD).
HSK31858 is characterized as an oral, potent, and highly selective small-molecule DPP1 inhibitor. It has previously been cleared for study in non-cystic fibrosis bronchiectasis (NCFBE). In November 2023, Chiesi Farmaceutici S.p.A, an Italian pharmaceutical company, entered into a licensing agreement with Haisco, securing development, manufacturing, and commercial rights to HSK31858 in markets outside Greater China.- Flcube.com
